StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pacira Pharmaceuticals (PCRX) PT Lowered to $32 at BMO Capital
February 16, 2018 6:11 AM
BMO Capital lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $32.00 (from $41.00) while maintaining a Market Perform ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Needham & Company Downgrades Pacira Pharmaceuticals (PCRX) to Hold
February 16, 2018 7:20 AM
Pacira Pharmaceuticals (PCRX) PT Lowered to $40 at Barclays
February 16, 2018 3:47 AM
Pacira Pharma (PCRX) Confirms Only Four FDA Committee Members Voted to Recommend Approval of EXPAREL sNDA
February 15, 2018 3:36 PM
Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
February 15, 2018 3:35 PM
Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
February 15, 2018 3:34 PM
Pacira Pharma (PCRX) Doesn't Win FDA Panel Backing of EXPAREL in 6 to 4 Vote Against Approval
February 15, 2018 3:01 PM
